Suppr超能文献

微切割前列腺癌中的杂合性缺失(LOH)、恶性肿瘤分级和克隆性

Loss of heterozygosity (LOH), malignancy grade and clonality in microdissected prostate cancer.

作者信息

Hügel A, Wernert N

机构信息

Institute of Pathology, University of Bonn, Germany.

出版信息

Br J Cancer. 1999 Feb;79(3-4):551-7. doi: 10.1038/sj.bjc.6690087.

Abstract

The aim of the present study was to find out whether increasing malignancy of prostate carcinoma correlates with an overall increase of loss of heterozygosity (LOH), and whether LOH typing of microdissected tumour areas can help to distinguish between multifocal or clonal tumour development. In 47 carcinomas analysed at 25 chromosomal loci, the overall LOH rate was found to be significantly lower in grade 1 areas (2.2%) compared with grade 2 (9.4%) and grade 3 areas (8.3%, P = 0.007). A similar tendency was found for the mean fractional allele loss (FAL, 0.043 for grade 1, 0.2 for grade 2 and 0.23 for grade 3, P = 0.0004). Of 20 tumours (65%) with LOH in several microdissected areas, 13 had identical losses at 1-4 loci within two or three areas, suggesting clonal development of these areas. Markers near RB, DCC, BBC1, TP53 and at D13S325 (13q21-22) showed higher loss rates in grades 2 and 3 (between 25% and 44.4%) compared with grade 1 (0-6.6%). Tumour-suppressor genes (TSGs) near these loci might, thus, be important for tumour progression. TP53 mutations were detected in 27%, but BBC1 mutations in only 7%, of samples with LOH. Evaluation of all 25 loci in every tumour made evident that each prostate cancer has its own pattern of allelic losses.

摘要

本研究的目的是确定前列腺癌恶性程度的增加是否与杂合性缺失(LOH)的总体增加相关,以及对显微切割肿瘤区域进行LOH分型是否有助于区分多灶性或克隆性肿瘤发展。在对25个染色体位点进行分析的47例癌中,发现1级区域的总体LOH率(2.2%)显著低于2级(9.4%)和3级区域(8.3%,P = 0.007)。平均等位基因缺失分数(FAL)也有类似趋势(1级为0.043,2级为0.2,3级为0.23,P = 0.0004)。在几个显微切割区域存在LOH的20例肿瘤(65%)中,13例在两三个区域的1 - 4个位点有相同的缺失,提示这些区域为克隆性发展。与1级(0 - 6.6%)相比,靠近RB、DCC、BBC1、TP53以及D13S325(13q21 - 22)处的标记在2级和3级中的缺失率更高(25%至44.4%)。因此,这些位点附近的肿瘤抑制基因(TSG)可能对肿瘤进展很重要。在存在LOH的样本中,27%检测到TP53突变,但只有7%检测到BBC1突变。对每个肿瘤的所有25个位点进行评估表明,每例前列腺癌都有其自身的等位基因缺失模式。

相似文献

引用本文的文献

3
Epigenetics in prostate cancer treatment.前列腺癌治疗中的表观遗传学
J Transl Genet Genom. 2021;5:341-356. doi: 10.20517/jtgg.2021.19. Epub 2021 Aug 27.
4
Clonal origin and spread of metastatic prostate cancer.转移性前列腺癌的克隆起源与扩散
Endocr Relat Cancer. 2016 Apr;23(4):R207-17. doi: 10.1530/ERC-16-0049. Epub 2016 Mar 21.
5
Tumor focality in prostate cancer: implications for focal therapy.前列腺癌的肿瘤局灶性:对局部治疗的影响。
Nat Rev Clin Oncol. 2011 Jan;8(1):48-55. doi: 10.1038/nrclinonc.2010.190. Epub 2010 Nov 23.
6
Cancer biomarker discovery: the entropic hallmark.癌症生物标志物的发现:熵的标志。
PLoS One. 2010 Aug 18;5(8):e12262. doi: 10.1371/journal.pone.0012262.

本文引用的文献

7
Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma.
J Urol. 1993 Nov;150(5 Pt 1):1427-33. doi: 10.1016/s0022-5347(17)35799-3.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验